Sunday, February 14, 2016

TearLab estimates Q4 revenue rose 28%

TearLab estimates Q4 revenue rose 28%

February 1, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) expects to report revenue of approximately $6.8-million for the fourth quarter of 2015, up about 28% from the same quarter in 2014. In addition, TearLab estimated that a net total of 258 TearLab Osmolality Systems were added in the fourth quarter of 2015, of which 200 were under the company’s new […]

BioLight reports positive TeaRx test results for DES

BioLight reports positive TeaRx test results for DES

January 7, 2016 by · Leave a Comment 

Tweet BioLight Israeli Life Sciences Investments (OTCQX: BLGTY; TASE: BOLT) has completed a second successful U.S. clinical study to assess the effectiveness of its TeaRx multi-assay test in evaluating tears’ components of healthy subjects as well as of patients suffering from dry eye syndrome (DES). The study, conducted by development partner Ora Inc., enrolled 74 […]

TearLab Q3 revenue climbs 27%

TearLab Q3 revenue climbs 27%

November 5, 2015 by · Leave a Comment 

Tweet Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter. “We delivered a strong growth quarter both sequentially and compared with the prior year by expanding our device base and continuing to establish the clinical […]

Medicare LCD confirms necessity of osmolarity testing in DED

Medicare LCD confirms necessity of osmolarity testing in DED

October 9, 2015 by · Leave a Comment 

Tweet First Coast Service Options, the Medicare area contractor for Florida, Puerto Rico and the U.S. Virgin Islands, has published a Local Coverage Determination (LCD) that confirms the role of tear osmolarity testing in the diagnosis and management of moderate-to-severe dry eye patients, according to TearLab (NASDAQ:TEAR; TSX:TLB). The First Coast LCD was recently published […]

TearLab names Wes Brazell as CFO

TearLab names Wes Brazell as CFO

July 6, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Wes Brazell as CFO, with overall responsibility for operational finance, financial reporting, budgeting and strategic planning, as well as helping to manage the company’s relationships and interactions with the investment community. He  succeeds William Dumencu, who will continue to support the company in a consulting role until the end […]

TearLab posts 28% increase in Q1 revenue

TearLab posts 28% increase in Q1 revenue

May 7, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) reported first quarter net revenue of $5.4-million, up 28% from $4.2-million for the same period in 2014. A total of 261 orders for TearLab systems were booked in the first quarter. “We started 2015 with a fully staffed sales force, a better understanding of implementation, and, as evidenced by the continuing […]

TearLab 2014 revenue climbs 35%

TearLab 2014 revenue climbs 35%

March 12, 2015 by · Leave a Comment 

Tweet 2014 net revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totalled $19.7-million, up 35% from $14.6-million in 2013. “2014 was a building year for us, with our primary focus being on improving the integration of the TearLab Osmolarity test into the daily routines of our customers,” CEO, Elias Vamvakas, said in a statement. “Moving into 2015, with an […]

TearLab in $35-million loan agreement with CRG

TearLab in $35-million loan agreement with CRG

March 5, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a term loan agreement with CRG and certain of its affiliate funds, which provides TearLab with up to $35-million of available borrowing capacity. Under the accord, CRG is initially providing TearLab with $15-million. Up to $20-million of additional funding will be available to TearLab, at its option, through […]

TearLab names Raymond Kong as VP sales

TearLab names Raymond Kong as VP sales

January 28, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Raymond Kong to its senior management team as VP of Sales. He succeeds Duane Morrison, who will shift his focus to major accounts and doctor networks in the newly created position of VP of business development. Most recently, Mr. Kong served as general manager for Alcon Laboratories’ Indonesia business, […]

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

January 5, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB), Dipexium Pharmaceuticals (NASDAQ:DPRX) and The Joint Corp. (NASDAQ:JYNT) were included in Feltl & Co.’s 2015 Top Idea List released today. Analyst Ben Haynor rates TearLab at “strong buy” with a price target of $5. The stock closed at $2.58 on Friday. TearLab has first-mover advantage in point-of-care diagnostics for dry eye […]

Next Page »

Email Newsletters with Constant Contact
Google+